JP2004155791A5 - - Google Patents

Download PDF

Info

Publication number
JP2004155791A5
JP2004155791A5 JP2004000542A JP2004000542A JP2004155791A5 JP 2004155791 A5 JP2004155791 A5 JP 2004155791A5 JP 2004000542 A JP2004000542 A JP 2004000542A JP 2004000542 A JP2004000542 A JP 2004000542A JP 2004155791 A5 JP2004155791 A5 JP 2004155791A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
metformin
hypoglycemic agent
acting hypoglycemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004000542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004155791A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2004155791A publication Critical patent/JP2004155791A/ja
Publication of JP2004155791A5 publication Critical patent/JP2004155791A5/ja
Withdrawn legal-status Critical Current

Links

JP2004000542A 1997-06-13 2004-01-05 新規niddm療法 Withdrawn JP2004155791A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK69497 1997-06-13
US6336897P 1997-10-29 1997-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50135099A Division JP2002500677A (ja) 1997-06-13 1998-06-12 新規niddm療法

Publications (2)

Publication Number Publication Date
JP2004155791A JP2004155791A (ja) 2004-06-03
JP2004155791A5 true JP2004155791A5 (enExample) 2005-09-15

Family

ID=26064473

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50135099A Withdrawn JP2002500677A (ja) 1997-06-13 1998-06-12 新規niddm療法
JP2004000542A Withdrawn JP2004155791A (ja) 1997-06-13 2004-01-05 新規niddm療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50135099A Withdrawn JP2002500677A (ja) 1997-06-13 1998-06-12 新規niddm療法

Country Status (12)

Country Link
US (1) US6677358B1 (enExample)
EP (2) EP1011673B1 (enExample)
JP (2) JP2002500677A (enExample)
AT (1) ATE201139T1 (enExample)
AU (1) AU7906898A (enExample)
DE (1) DE69800806T2 (enExample)
DK (1) DK1011673T3 (enExample)
ES (1) ES2159184T3 (enExample)
GR (1) GR3036078T3 (enExample)
PT (1) PT1011673E (enExample)
WO (1) WO1998056378A1 (enExample)
ZA (1) ZA985126B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
JP4175662B2 (ja) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ.ヴイ. 電気的筋肉制御装置
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
RU2280447C2 (ru) * 1999-09-17 2006-07-27 Новартис Аг Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
KR20020063260A (ko) 1999-12-23 2002-08-01 노파르티스 아게 당 대사 장애를 치료하기 위한 혈당강하제의 용도
WO2001047557A1 (en) 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Oral preparations for diabetes
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
AU784422B2 (en) 2000-02-01 2006-03-30 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
JP4424203B2 (ja) * 2002-04-26 2010-03-03 味の素株式会社 糖尿病予防・治療剤
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
WO2006119467A2 (en) 2005-05-04 2006-11-09 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
EP2026787B1 (en) * 2006-05-13 2013-12-25 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
US20100029721A1 (en) * 2006-09-29 2010-02-04 Novo Nordisk A/S Pharmaceutical Formulation Comprising Metformin and Repaglinide
CN101756971B (zh) * 2008-10-09 2013-09-18 北京德众万全药物技术开发有限公司 一种盐酸二甲双胍瑞格列奈的口服固体药物组合物
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
WO2014102715A1 (en) 2012-12-24 2014-07-03 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
WO2018034627A1 (en) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Pharmaceutical composition of antidiabetic tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
DK0589874T3 (da) 1991-06-21 2000-04-03 Boehringer Ingelheim Pharma Anvendelse af (S) (+) -2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl ]aminocarbonylmethyl]-benzoesyre til fremstil

Similar Documents

Publication Publication Date Title
JP2004155791A5 (enExample)
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
WO2007090091A3 (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP2005512995A5 (enExample)
IL236426B (en) Use of a compound in combination with bortezomib to prepare a drug for a neoplastic disease and a pharmaceutical preparation containing a compound and bortezomib
JP2005512997A5 (enExample)
BRPI0309544B8 (pt) preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
DE60310039D1 (de) Pharmazeutische tablette
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
IL181382A0 (en) Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
NZ521799A (en) Sustained release paracetamol composition
ITMI20032473A1 (it) Farmaci in polvere contenenti un sale di tiotropio e salmeterolo xinafoato
HUP0004966A3 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
JP2012533559A5 (enExample)
EP1221926A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POOR SOLVENT MEDICAMENTS
JP2008515980A5 (enExample)
JP2009516719A5 (enExample)
ATE373488T1 (de) Antimykobakterielle pharmazeutische zusammensetzung mit einem arzneimittel gegen tuberkulose
JP2006342148A5 (enExample)
WO2005004836A3 (en) Saquinavir mesylate oral dosage form
JP2005513105A5 (enExample)
JP2009536193A5 (enExample)
JP2006516279A5 (enExample)
DE602004000016D1 (de) Schnell freisetzende farmazeutische darreichungsform enthaltend polymorphes tibolon
JP2008540603A5 (enExample)